L&K BIOMED CO., LTD.

156100KOSDAQMedical, precision and optical instruments

L&K BIOMED CO., LTD. (156100, KOSDAQ) reported KRW 39bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2023302-56331Consolidated
202436398336Consolidated
2025391-178339Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
20236.8%-17.5%48.7%-17.1%
20248.5%25.4%43.4%25.4%
20251.8%-43.1%46.3%-43.5%

Revenue moved 30.1% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 116bn
Close priceKRW 5,200
Listed shares22,351,153
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)97
Women34 (35.1%)
Average tenure2.7 years
Annual pay, menKRW 65,000,000
Annual pay, womenKRW 52,000,000
Pay ratio, women to men80%

Other companies in Medical, precision and optical instruments

102 listed companies file under this classification. Showing 12.

See the whole Medical, precision and optical instruments list →